Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

IV infusion set on light blue background, top view. Space for text

Pipeline

BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.

April 3, 2025

2 min read

Tristan Manalac

FDA

FDA Misses Review Deadline for Novavax’s COVID-19 Shot, Days After Marks’ Resignation

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1, but the agency’s principal deputy commissioner intervened.

April 3, 2025

2 min read

Tristan Manalac

Government

Trump Tariffs Miss Pharma For Now, But Uncertainties Loom

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”

April 3, 2025

2 min read

Tristan Manalac

Illustration showing hands pointing to alarm clock

Job Trends

Over Half of Biopharma Professionals Work More Hours Than Average US Workers, BioSpace Finds

Although U.S. full-time employees worked an average of 42.9 hours weekly last year, according to Gallup, that wasn’t true for most BioSpace LinkedIn poll respondents. A Karius HR executive discusses a few potential reasons for the longer workweeks.

April 3, 2025

3 min read

Angela Gabriel

FDA

Scott Steele Steps In as FDA’s Interim CBER Head After Marks’ Departure

Following the dramatic late-night resignation of Peter Marks last Friday, Steele, a senior advisor to the division, takes the reins in a department inside an agency beset by cuts, layoffs, and confusion.

April 2, 2025

3 min read

Dan Samorodnitsky

Brain , concept idea art of thinking, surreal portrait painting, conceptual artwork, 3d illustration

Neurodegenerative disease

Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, which today began a rolling BLA for accelerated approval.

April 2, 2025

5 min read

Dan Samorodnitsky

Outline of two people moving through revolving doorway

FDA

FDA Job Cuts, Key Departures Bring ‘Revolving Door’ Debate Front and Center

With the recently announced layoffs of 3,500 FDA staffers and exits of branch directors Patrizia Cavazzoni and Peter Marks, there could be a wealth of talent available to biopharma companies. Does this pose an ethical quandary? It depends on who you ask.

April 2, 2025

6 min read

Heather McKenzie

Aerial top down view of a large container cargo ship in motion over open ocean with copy space

Government

Drugmakers Ask Trump for Staggered Tariffs as ‘Liberation Day’ Arrives

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma industry are “underappreciated.”

April 2, 2025

2 min read

Tristan Manalac